China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug
02/07/2026 09:55
China's CSPC Pharmaceutical Group to partner with AstraZeneca for renal disease drug July 2 (Reuters) - CSPC Pharmaceutical Group 1093.HK said on Thursday it had entered into an agreement with London-listed AstraZeneca AZN.L to jointly develop pre-clinical candidates with potential to treat renal diseases using the group's siRNA drug discovery platform.
AstraZeneca will have the option to obtain the exclusive rights for the development, manufacturing and commercialisation of the drug globally or outside of China in exchange for payments totalling $1.77 billion, including an upfront payment of $30 million, the group added.
(Reporting by Sherin Sunny in Bengaluru)
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines